Stock listing

NASDAQ:RVPH Reviva Pharmaceuticals Holdings, Inc. Stock

Home listing (NASDAQ) of Reviva Pharmaceuticals Holdings, Inc.

Follow Reviva Pharmaceuticals Holdings, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RVPH

$0.281 USD -0.019 (-6.3%)

Close on Nov 20, 2026

Past year -97.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.281 – $0.335 USDNov 20, 2026
Volume
5,455 sharesNov 20, 2026
Market cap
$3.68M USDAt the close on Nov 20, 2026 · price × 13.11M shares outstanding
52-week range
$0.262 – $15.400 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$11,896 USDMedian day 19,291 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Reviva Pharmaceuticals Holdings, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RVPH · Home$0.281 USD-0.019 (-6.3%)5,455$0.291$0.335$0.281$0.300Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RVPH · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.281-0.019-6.3%$0.291$0.335$0.2815,455
$0.300-0.007-2.1%$0.280$0.390$0.2802,330
$0.307+0.007+2.2%$0.300$0.307$0.3001,215
$0.300-0.040-11.8%$0.340$0.363$0.28019,887
$0.340+0.0000.0%$0.340$0.420$0.3407,016
$0.3400.0000.0%$0.340$0.340$0.340498
$0.340-0.035-9.4%$0.354$0.420$0.33810,503
$0.375+0.055+17.3%$0.330$0.417$0.3304,079
$0.320-0.048-12.9%$0.370$0.417$0.31913,226
$0.368+0.028+8.1%$0.340$0.370$0.31947,980
$0.340-0.040-10.5%$0.350$0.400$0.31530,864
$0.380-0.021-5.2%$0.374$0.466$0.31045,722
$0.401-0.028-6.5%$0.416$0.434$0.37419,322
$0.429+0.079+22.6%$0.350$0.451$0.31254,452
$0.350-0.042-10.6%$0.400$0.403$0.314110,080
$0.392-0.023-5.7%$0.390$0.460$0.3909,742
$0.415-0.035-7.8%$0.440$0.450$0.40323,255
$0.450+0.024+5.7%$0.420$0.480$0.41011,444
$0.426-0.022-5.0%$0.433$0.500$0.41139,612
$0.448-0.027-5.7%$0.405$0.500$0.40513,017
$0.475+0.031+7.0%$0.480$0.480$0.43128,875
$0.444-0.016-3.5%$0.430$0.500$0.43027,458
$0.460+0.010+2.2%$0.443$0.500$0.38532,423
$0.450-0.020-4.4%$0.470$0.500$0.45033,977
$0.471-0.005-0.9%$0.495$0.512$0.45038,463
$0.475-0.003-0.7%$0.485$0.530$0.47094,660
$0.478-0.017-3.5%$0.461$0.485$0.46123,544
$0.495+0.005+1.1%$0.510$0.510$0.46115,234
$0.490-0.010-2.0%$0.480$0.500$0.44117,554
$0.500+0.005+1.0%$0.480$0.500$0.48011,914
$0.495-0.005-1.0%$0.500$0.530$0.49521,108
$0.500-0.011-2.2%$0.500$0.530$0.50057,246
$0.511+0.001+0.2%$0.500$0.540$0.50019,259
$0.510+0.010+2.0%$0.478$0.520$0.47042,354
$0.5000.0000.0%$0.470$0.510$0.47059,250
$0.500+0.030+6.4%$0.480$0.500$0.4709,953
$0.470-0.007-1.5%$0.470$0.504$0.47012,236
$0.477-0.001-0.2%$0.490$0.520$0.47059,648
$0.478-0.002-0.4%$0.480$0.528$0.47814,468
$0.480-0.040-7.7%$0.478$0.500$0.4787,317
$0.520+0.040+8.3%$0.500$0.528$0.4806,570
$0.480-0.048-9.1%$0.494$0.520$0.4807,181
$0.528+0.028+5.6%$0.490$0.528$0.47010,000
$0.500+0.020+4.2%$0.480$0.529$0.47818,998
$0.480-0.022-4.4%$0.480$0.529$0.48030,390
$0.502+0.012+2.5%$0.490$0.529$0.49010,013
$0.490+0.010+2.1%$0.500$0.529$0.4809,991
$0.4800.0000.0%$0.480$0.530$0.48028,430
$0.480-0.055-10.3%$0.535$0.535$0.47018,797
$0.535+0.035+7.0%$0.500$0.535$0.50050,655
$0.500-0.032-6.1%$0.555$0.555$0.50012,174
$0.533-0.006-1.1%$0.500$0.555$0.49035,084
$0.539+0.008+1.6%$0.510$0.555$0.50012,144
$0.5300.0000.0%$0.510$0.555$0.5001,893
$0.530-0.010-1.9%$0.530$0.555$0.51023,593
$0.540+0.005+0.9%$0.550$0.555$0.49031,709
$0.535+0.025+4.9%$0.490$0.535$0.48039,542
$0.510+0.030+6.3%$0.480$0.520$0.47018,184
$0.480-0.038-7.4%$0.530$0.530$0.47039,768
$0.519+0.014+2.8%$0.500$0.520$0.50013,897
$0.505-0.001-0.1%$0.480$0.515$0.47017,592
$0.505+0.010+2.1%$0.460$0.520$0.45067,042
$0.495+0.016+3.4%$0.500$0.510$0.4607,298
$0.479-0.005-0.9%$0.482$0.510$0.46034,494
$0.483-0.007-1.4%$0.530$0.530$0.48027,477
$0.490-0.010-2.0%$0.518$0.535$0.46031,077

Splits

1 split · NASDAQ:RVPH · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:RVPH
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Reviva Pharmaceuticals Holdings, Inc. news

Reviva Pharmaceuticals Holdings, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
9 in the last 12 months · 92 in all · newest Jun 23, 2026 · oldest 2021
Decks
5 decks · latest Jun 2, 2025

Where Reviva Pharmaceuticals Holdings, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RVPH · Home listing · This pageNASDAQUnited StatesUSD
BOATS:RVPHBOATSUnited StatesUSD

Valuation

Price/book 0.3× against a median of 0.9×: 2nd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$13.77M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.57

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Reviva Pharmaceuticals Holdings, Inc. · NASDAQ:RVPHUS$3.68M−US$13.77Mn/an/an/a0.3×n/a0.0×1.57
AdAlta Ltd. · ASX:1ADUS$4.25MUS$3.40Mn/an/an/a17.4×n/a0.0×n/a
Percheron Therapeutics Limited · ASX:PERUS$3.94MUS$1.27Mn/an/an/a0.8×n/a0.0×n/a
Lantern Pharma Inc. · NASDAQ:LTRNUS$3.89M−US$3.69Mn/an/an/a2.8×n/a0.0×2.80
Silo Pharma, Inc. · NASDAQ:SILOUS$3.77M−US$4.28Mn/an/an/a0.5×n/a0.0×1.23
Alzamend Neuro, Inc. · NASDAQ:ALZNUS$3.74M−US$3.85Mn/an/an/a0.7×n/a0.0×2.00
Biotron Limited · ASX:BITUS$3.69MUS$2.66Mn/an/an/a1.9×n/a0.0×n/a
Liminatus Pharma, Inc. · NASDAQ:LIMNUS$3.37MUS$1.80Mn/an/an/a11.2×n/a4.8×0.94
Xenetic Biosciences, Inc. · NASDAQ:XBIOUS$3.28M−US$2.53Mn/a−0.8×n/a0.7×−123.7%0.0×1.46
Aprea Therapeutics, Inc. · NASDAQ:APREUS$3.25M−US$34.60Mn/an/an/a0.1×n/a0.0×0.73
Spago Nanomedical AB · OMXSTO:SPAGOUS$3.20MUS$22,063n/a5.6×n/a1.0×n/a0.0×n/a
Median of the othersUS$3.72M−US$1.25M2.4×0.9×−123.7%0.0×1.35

Forecasts

3 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
17.50 USD · Analysts' mean
EPS, year to Dec 2026
-0.85 · 1 analyst

Team and board

OfficerRole
Bruce MackleInvestor Relations
PJ KelleherInvestor Relations
Greg YoungVP Corporate Services

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026−11.8%
Q2 2026Aug 13, 2026 · After close+1.1%
Q1 2026May 13, 2026 · After close+10.8%
Q4 2025Mar 23, 2026+3.4%
Q3 2025Nov 13, 2025 · After close−7.2%
Q2 2025Aug 14, 2025 · After close+15.8%
Q1 2025May 15, 2025 · After close−2.3%
Q4 2024Mar 31, 2025−38.5%
Q3 2024Nov 14, 2024 · After close−7.0%
Q2 2024Aug 14, 2024 · Before open+4.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open+7.3%
Q4 2023Mar 19, 2024 · After close−1.4%
Q3 2023Nov 14, 2023 · After close−8.8%
Q2 2023Aug 14, 2023 · After close+2.4%
Q1 2023May 15, 2023 · After close−3.1%
Q4 2022Mar 30, 2023 · Before open−10.1%
Q3 2022Nov 14, 2022 · After close−20.4%
Q2 2022Aug 15, 2022 · After close−11.6%
Q1 2022May 16, 2022 · After close+8.0%
Q4 2021Mar 15, 2022 · After close+4.7%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (June 2025)Technical41 slidesJun 2, 2025
Investor Presentation (March 2021)Investor deck23 slidesMar 4, 2021
Tenzing Acquisition — SPAC Merger (November 2020)SPAC merger29 slidesNov 6, 2020
Tenzing Acquisition — SPAC Merger (October 2020)SPAC merger28 slidesOct 6, 2020
SPAC Merger (July 2020)SPAC merger28 slidesJul 29, 2020

Open Decks

Financings

RaiseDate
Public offering of shares of common stock (or common stock equivalents) with Series E and Series F warrants
Update: about US$9M · US$0.335 a share · Warrants at US$0.335 · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Use of proceeds: Research and development activities, working capital and other general corporate purposes
Sep 19, 2025
Public offering of public equity offering
Closed: US$10M raised · US$0.5 a share · Warrants at US$0.5 · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Use of proceeds: Research and development activities, working capital and other general corporate purposes
Aug 14, 2025
Public offering of shares of common stock (or common share equivalents) and warrants
Announced: about US$18M · US$1.5 a share · Warrants at US$1.5 · Citizens JMP +1
Dealers: Citizens JMP (lead), Citizens JMP Securities, LLC (lead)
Use of proceeds: Fund research and development activities and for working capital and other general corporate purposes
Dec 16, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Tenzing Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on Aug 20, 2018.

Price
US$10.00 a unit
Units offered
5,500,000 units
Offering size
US$55 million
Underwriters' option
Up to 825,000 more units
Listing
TZACU on the Nasdaq Capital Market
Underwriter
Maxim Group LLC
Units delivered
On or about Aug 23, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceJun 19, 2018
Filed publiclyJul 20, 2018
Amended twiceNewest Aug 16, 2018
Shares registered with an exchangeAug 20, 2018
Declared effective by the SECAug 20, 2018
Final prospectus, with the priceAug 22, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Aug 22, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019
Research and development11.7M22.9M31.4M22.9M4.85M295.1K195.7K
Operating income-20.2M-30.8M-39.5M-28.2M-10.1M-2.43M-724.7K-376.9K
Depreciation and amortization0591645
EBITDA-10.1M-2.43M-376.2K
Interest expense13.4K18.5K33.7K1.45M469.4K
Income before tax-19.8M-29.9M-39.2M-28.2M-8.52M-3.78M-846.0K
Income tax18.9K19.5K16.9K20.8K6.00K8000800
Net income-19.9M-29.9M-39.3M-28.3M-8.52M-3.78M617.9K-846.8K
Earnings per share, basic-5.48-17.73-1.65-1.45-0.58-1.24-0.21-0.31
Earnings per share, diluted-1.24-0.21-0.31

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019
Cash and equivalents14.4M13.5M23.4M18.5M29.7M8.76M69.3K193
Current assets15.1M14.7M23.7M138.9K
Property, plant and equipment0591
Total assets15.9M15.5M23.7M18.9M31.4M8.76M61.0M2.60K
Accounts payable3.01M6.28M3.85M3.52M509.6K1.01M299.7K224.5K
Current liabilities7.28M14.6M17.2M9.96M2.34M1.33M299.7K
Total liabilities7.28M14.7M18.0M10.5M2.72M3.30M3.26M6.81M
Shareholders' equity8.65M812.6K5.72M8.39M28.7M5.47M5.00M-6.81M
Shares outstanding5.87M2.36M27.9M20.4M14.4M9.23M2.70M15.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019
Cash from operations-24.6M-33.5M-28.3M-19.0M-10.7M-4.07M-426.6K-218.4K
Cash from investing5.70M
Cash from financing25.6M23.7M33.2M7.79M31.6M12.8M-5.52M100.0K
Change in cash962.5K-9.89M4.85M-11.2M20.9M8.76M-243.8K-118.4K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
ARS · Annual report to shareholdersNov 9, 2026Annual reportSEC
DEF 14A · Proxy statementNov 9, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 29, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 3, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 31, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
25-NSEJul 10, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
8-K · Current reportMay 13, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 7, 2026Big-stake noticeSEC
8-K · Current reportApr 15, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMar 30, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 30, 2026Offer documentSEC
8-K · Current reportMar 30, 2026ResultsSEC
10-K · Annual reportMar 27, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeMar 25, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 24, 2026Big-stake noticeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
8-K · Current reportMar 19, 2026Material contractSEC
424B5 · ProspectusMar 19, 2026Offer documentSEC
424B5 · ProspectusMar 18, 2026Offer documentSEC
8-K · Current reportMar 5, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportJan 23, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 16, 2026Big-stake noticeSEC
8-K · Current reportDec 23, 2025Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 22, 2025Big-stake noticeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
25-NSEDec 12, 2025Other filingsSEC
DEFA14A · Additional proxy materialDec 5, 2025Meeting noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
ARS · Annual report to shareholdersNov 4, 2025Annual reportSEC
DEFA14A · Additional proxy materialNov 4, 2025Meeting noticeSEC
DEF 14A · Proxy statementNov 4, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 24, 2025Meeting noticeSEC
8-K · Current reportOct 17, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 29, 2025Big-stake noticeSEC
8-K · Current reportSep 26, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 24, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 24, 2025Big-stake noticeSEC
8-K · Current reportSep 19, 2025Material contractSEC
424B5 · ProspectusSep 19, 2025Offer documentSEC
424B5 · ProspectusSep 18, 2025Offer documentSEC
8-K · Current reportAug 14, 2025ResultsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 1, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 1, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 1, 2025Big-stake noticeSEC
8-K · Current reportJun 26, 2025Material contractSEC
424B5 · ProspectusJun 26, 2025Offer documentSEC
424B5 · ProspectusJun 25, 2025Offer documentSEC
8-K · Current reportJun 6, 2025Current reportSEC
8-K · Current reportJun 2, 2025Current reportSEC
424B5 · ProspectusMay 30, 2025Offer documentSEC
8-K · Current reportMay 30, 2025Material contractSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 15, 2025ResultsSEC
S-8 · Registration statement for employee plansApr 3, 2025Offer documentSEC
10-K · Annual reportApr 2, 2025Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
8-K · Current reportMar 31, 2025ResultsSEC
8-K · Current reportFeb 18, 2025Management or board changeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 31, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 23, 2024Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 20, 2024Big-stake noticeSEC
424B5 · ProspectusDec 18, 2024Offer documentSEC
8-K · Current reportDec 17, 2024Material contractSEC
424B5 · ProspectusDec 16, 2024Offer documentSEC
8-K · Current reportDec 16, 2024Current reportSEC
8-K · Current reportDec 12, 2024Meeting outcomeSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 12, 2024Current reportSEC
ARS · Annual report to shareholdersOct 28, 2024Annual reportSEC
DEF 14A · Proxy statementOct 28, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 17, 2024Meeting noticeSEC
8-K · Current reportSep 17, 2024Management or board changeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 23, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedAug 23, 2024Big-stake noticeSEC
8-K/A · Current report, amendedAug 22, 2024Material contractSEC
UPLOAD · Letter from the SECAug 22, 2024Other filingsSEC
424B5 · ProspectusAug 22, 2024Offer documentSEC
8-K · Current reportAug 21, 2024Material contractSEC
SC 13G · Big-stake noticeAug 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
CORRESP · Letter to the SECAug 7, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 24, 2024Other filingsSEC
8-K · Current reportJul 9, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedMay 31, 2024Big-stake noticeSEC
8-K · Current reportMay 29, 2024Material contractSEC
424B5 · ProspectusMay 28, 2024Offer documentSEC
S-8 · Registration statement for employee plansMay 17, 2024Offer documentSEC
8-K · Current reportMay 15, 2024Current reportSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
8-K · Current reportApr 15, 2024Current reportSEC
10-K · Annual reportApr 15, 2024Annual reportSEC
8-K · Current reportApr 15, 2024ResultsSEC
8-K · Current reportApr 15, 2024ResultsSEC
NT 10-K · Late filing noticeApr 2, 2024Explanation requestSEC
SC 13D/A · Big-stake notice, amendedFeb 16, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveFeb 14, 2024Other filingsSEC
424B4 · ProspectusFeb 13, 2024Offer documentSEC
UPLOAD · Letter from the SECFeb 9, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 9, 2024Other filingsSEC
S-3 · Registration statementFeb 2, 2024Offer documentSEC
SC 13D/A · Big-stake notice, amendedNov 30, 2023Big-stake noticeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
8-K · Current reportNov 17, 2023Material contractSEC
424B5 · ProspectusNov 17, 2023Offer documentSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
8-K · Current reportNov 14, 2023Meeting outcomeSEC
8-K/A · Current report, amendedNov 14, 2023Current reportSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
8-K · Current reportOct 30, 2023Current reportSEC
ARS · Annual report to shareholdersOct 4, 2023Annual reportSEC
DEF 14A · Proxy statementOct 4, 2023Meeting noticeSEC
8-K · Current reportOct 4, 2023Current reportSEC
8-K · Current reportAug 17, 2023Current reportSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
8-K · Current reportJul 24, 2023Current reportSEC
8-K · Current reportJun 23, 2023Current reportSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
8-K · Current reportMay 15, 2023ResultsSEC
SC 13D/A · Big-stake notice, amendedMay 5, 2023Big-stake noticeSEC
4 · Change in ownershipApr 27, 2023Insider tradeSEC
8-K · Current reportApr 27, 2023Management or board changeSEC
4 · Change in ownershipApr 27, 2023Insider tradeSEC
424B3 · ProspectusApr 5, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 5, 2023Other filingsSEC
S-8 · Registration statement for employee plansMar 30, 2023Offer documentSEC
POS AM · Amendment to an effective registrationMar 30, 2023Offer documentSEC
10-K · Annual reportMar 30, 2023Annual reportSEC
8-K · Current reportMar 30, 2023ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
8-K · Current reportJan 4, 2023Current reportSEC
4 · Change in ownershipNov 21, 2022Insider tradeSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportNov 14, 2022ResultsSEC
4 · Change in ownershipNov 14, 2022Insider tradeSEC
4 · Change in ownershipNov 14, 2022Insider tradeSEC
4 · Change in ownershipNov 14, 2022Insider tradeSEC
8-K · Current reportNov 14, 2022Meeting outcomeSEC
4 · Change in ownershipNov 14, 2022Insider tradeSEC
424B4 · ProspectusOct 18, 2022Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 18, 2022Other filingsSEC
CORRESP · Letter to the SECOct 13, 2022Other filingsSEC
UPLOAD · Letter from the SECOct 12, 2022Other filingsSEC
DEF 14A · Proxy statementOct 11, 2022Meeting noticeSEC
S-1 · Registration statementOct 6, 2022Offer documentSEC
4 · Change in ownershipOct 3, 2022Insider tradeSEC
DSep 19, 2022Other filingsSEC
SC 13D/A · Big-stake notice, amendedSep 12, 2022Big-stake noticeSEC
4 · Change in ownershipSep 12, 2022Insider tradeSEC
8-K · Current reportSep 7, 2022Material contractSEC
424B5 · ProspectusSep 7, 2022Offer documentSEC
8-K · Current reportAug 15, 2022ResultsSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
8-K · Current reportJul 28, 2022Current reportSEC
8-K · Current reportJul 27, 2022Current reportSEC
4 · Change in ownershipJun 30, 2022Insider tradeSEC
8-K · Current reportJun 27, 2022Management or board changeSEC
10-Q · Quarterly reportMay 16, 2022Quarterly reportSEC
8-K · Current reportMay 16, 2022ResultsSEC

This page holds 200 of 417 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Reviva Pharmaceuticals Holdings, Inc.’s releases · as of Aug 14, 2025

Common shares
13,110,377
Fully diluted
13,110,377

Fully diluted

LineShares
Common shares13,110,377

Warrants and options

Lot
Warrants · US$0.50 · expiry not stated

Share count over time

CountShares
Nov 22, 202613,110,377

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyAs of
Miller Global Investments, LLC1<0.01%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Nasdaq Composite Index Fund998<0.01%US$408May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Integrated Core Strategies (US) LLC8.20%1.07MJun 30, 2026Schedule 13G
Parag Saxena2.80%363KMar 20, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Nina B Shapiro
Other companies: Aeries Technology, Inc. (Director · Since at least Nov 6, 2023); Eucrates Biomedical Acquisition Corp. (Director · Oct 23, 2020 – Oct 23, 2020 · Past); Identiv, Inc. (Director · Jun 28, 2016 – Jun 1, 2022 · Past)
Director · Aug 20, 2018 – Aug 20, 2018 · Past
William I Campbell
Other companies: Eucrates Biomedical Acquisition Corp. (Director · Oct 23, 2020 – Oct 23, 2020 · Past); The KeyW Holding Corporation (Director · Jul 1, 2016 – Jun 11, 2019 · Past)
Director · Aug 20, 2018 – Aug 20, 2018 · Past
Gonzalo Cordova
Other companies: Eucrates Biomedical Acquisition Corp. (Chief Financial Officer · Oct 23, 2020 – Oct 23, 2020 · Past)
Chief Financial Officer · Aug 20, 2018 – Aug 20, 2018 · Past
Leslie D Funtleyder
Other companies: Applied Therapeutics Inc (Chief Financial Officer, Director · Since at least Oct 1, 2020)
Director · Since at least Jun 15, 2021
Parag Saxena
Other companies: Eucrates Biomedical Acquisition Corp. (Chief Executive Officer, Director · Oct 23, 2020 – Nov 24, 2020 · Past)
Director · Since at least Aug 20, 2018
Bruce MackleInvestor Relations · Since at least Jun 5, 2025
Greg YoungVP Corporate Services · Since at least Jun 23, 2026
Laxminarayan BhatPresident and CEO, Director · Since at least Dec 14, 2020
Marc CantillonChief Medical Officer · Dec 14, 2020 – Dec 14, 2020 · Past
Narayan PrabhuChief Financial Officer · Since at least Mar 18, 2026
All 15 people
PersonSeat
PJ KelleherInvestor Relations · Since at least Jun 23, 2026
Purav PatelDirector · Since at least Dec 14, 2020
Rahul NayarChief Executive Officer, Director · Aug 20, 2018 – Aug 30, 2018 · Past
Richard A MargolinDirector · Since at least Dec 14, 2020
Vikas ThaparDirector · Aug 20, 2018 – Aug 20, 2018 · Past

Open People

Log in to ask 6ix AI your own questions about Reviva Pharmaceuticals Holdings, Inc.